Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, PhD.; hereinafter "Shionogi") and Jordan's Guardian Angels announced a research collaboration between their ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Management reiterated its full-year revenue target of JPY460 billion and emphasized achieving JPY550 billion in FY2025. Growth is expected from the HIV franchise, global expansion of Xocova, and ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load.

Shionogi & Co (($JP:4507)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Shionogi & Co.

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria plus Rekambys for HIV treatment in adolescents: London, UK Saturday, February 1, 2025, 11:00 Hrs ...

London: GSK plc has announced that ViiV Healthcare, the global HIV company majority owned by GSK, with Pfizer and Shionogi as ...